|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.920 USD | +1.74% |
|
+4.64% | +89.67% |
| 08/05 | Immix Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 29/04 | Mizuho Keeps Price Target on Immix Biopharma to $15, Maintains Outperform Rating | MT |
| Capitalization | 53Cr 45Cr 41Cr 39Cr 72Cr 5.01TCr 72Cr 484.68Cr 189.18Cr 2.39TCr 197.31Cr 193.17Cr 8.26TCr | P/E ratio 2026 * |
-12.2x | P/E ratio 2027 * | -14.8x |
|---|---|---|---|---|---|
| Enterprise value | 46Cr 39Cr 36Cr 34Cr 63Cr 4.4TCr 64Cr 425.23Cr 165.98Cr 2.09TCr 173.11Cr 169.48Cr 7.24TCr | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 8.3x |
| Free-Float |
77.89% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +1.74% | ||
| 1 week | +4.64% | ||
| Current month | +11.09% | ||
| 1 month | +7.13% | ||
| 3 months | +45.03% | ||
| 6 months | +207.12% | ||
| Current year | +89.67% |
| 1 week | 9.18 |  | 10.38 |
| 1 month | 8.3 | | 10.54 |
| Current year | 4.18 | | 11.61 |
| 1 year | 1.87 | | 11.61 |
| 3 years | 1.26 | | 11.61 |
| 5 years | 0.68 | | 11.61 |
| 10 years | 0.68 | | 11.61 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ilya Rachman
CEO | Chief Executive Officer | 54 | 01/01/2012 |
Gabriel Morris
DFI | Director of Finance/CFO | 40 | 01/03/2021 |
Graham Ross
CTO | Chief Tech/Sci/R&D Officer | 66 | 01/06/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Ilya Rachman
CHM | Chairman | 54 | 01/01/2012 |
Gabriel Morris
BRD | Director/Board Member | 40 | 01/03/2021 |
Helen Adams
BRD | Director/Board Member | 67 | 01/06/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.74% | +4.64% | +374.64% | +352.97% | 53Cr | |
| +3.04% | +0.99% | +39.35% | +87.67% | 5.07TCr | |
| +1.80% | -0.76% | +84.08% | +60.38% | 4.86TCr | |
| -0.83% | -6.05% | +0.61% | -9.01% | 2.36TCr | |
| +2.51% | -25.80% | +59.63% | +448.23% | 2.25TCr | |
| +2.18% | -0.24% | +45.20% | -26.69% | 1.75TCr | |
| +1.07% | -2.84% | +25.78% | -42.17% | 1.61TCr | |
| -0.99% | +1.80% | +63.65% | +205.76% | 1.54TCr | |
| +3.21% | +9.89% | -22.12% | +869.35% | 1.45TCr | |
| +2.00% | +0.31% | +49.35% | - | 1.34TCr | |
| Average | +1.58% | -2.41% | +72.02% | +216.28% | 2.23TCr | |
| Weighted average by Cap. | +1.76% | -3.05% | +45.61% | +153.18% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 5.64Cr 4.79Cr 4.38Cr 4.13Cr 7.71Cr 537.47Cr 7.77Cr 52Cr 20Cr 255.98Cr 21Cr 21Cr 885.82Cr |
| Net income | -4.22Cr -3.58Cr -3.28Cr -3.09Cr -5.76Cr -401.82Cr -5.81Cr -39Cr -15Cr -191.37Cr -16Cr -15Cr -662.24Cr | -4.34Cr -3.68Cr -3.37Cr -3.18Cr -5.93Cr -413.24Cr -5.98Cr -40Cr -16Cr -196.81Cr -16Cr -16Cr -681.08Cr |
| Net Debt | -6.45Cr -5.47Cr -5.01Cr -4.73Cr -8.81Cr -614.47Cr -8.89Cr -59Cr -23Cr -292.65Cr -24Cr -24Cr -1.01TCr | -5.76Cr -4.89Cr -4.48Cr -4.22Cr -7.87Cr -548.68Cr -7.93Cr -53Cr -21Cr -261.31Cr -22Cr -21Cr -904.3Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/26/11 | 9.920 $ | +1.74% | 6,58,634 |
| 08/26/08 | 9.750 $ | +2.20% | 6,61,325 |
| 07/26/07 | 9.540 $ | -7.56% | 6,49,592 |
| 06/26/06 | 10.32 $ | +7.95% | 11,19,796 |
| 05/26/05 | 9.560 $ | +0.84% | 9,01,086 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IMMX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition